Fingerprint
Dive into the research topics of 'First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically